Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.78 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | PDE9A | O76083 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465272 | 0.88 | AR (1.00) | ARCYP11B2CYP11B1PDE9APDE1C | |
| SCHEMBL6464186 | 0.85 | AR (0.81) | ARCYP11B2CYP11B1PDE9APDE1C | |
| SCHEMBL6469609 | 0.82 | AR (0.70) | ARCYP11B2CYP11B1PDE9A | |
| SCHEMBL6465363 | 0.82 | AR (0.76) | ARCYP11B2CYP11B1PDE9APDE1C | |
| SCHEMBL6464828 | 0.80 | AR (0.77) | ARCYP11B2CYP11B1PTGDR2 | |
| SCHEMBL6466418 | 0.80 | AR (0.80) | ARCYP11B2CYP11B1PDE9APDE1C | |
| SCHEMBL6889299 | 0.77 | AR (0.72) | ARCYP11B2PTGDR2 | |
| SCHEMBL6469473 | 0.77 | AR (0.66) | ARCYP11B2CYP11B1 | |
| SCHEMBL6464888 | 0.77 | AR (0.77) | ARCYP11B2CYP11B1PTGDR2 | |
| SCHEMBL6468892 | 0.76 | AR (0.77) | ARCYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1466902-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | SHBG, PRLHR, FSHR | AR 6/4885CYP11B2 151/4885CYP11B1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.